# Efavirenz for the Treatment of Creutzfeldt-Jakob Disease

> **NCT07482085** · PHASE3 · NOT_YET_RECRUITING · sponsor: **Xuanwu Hospital, Beijing** · enrollment: 246 (estimated)

## Conditions studied

- Creutzfeldt-Jakob Disease

## Interventions

- **DRUG:** Efavirenz
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT07482085
- **Lead sponsor:** Xuanwu Hospital, Beijing
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-03
- **Primary completion:** 2028-12
- **Final completion:** 2028-12
- **Target enrollment:** 246 (ESTIMATED)
- **Last updated:** 2026-03-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07482085

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07482085, "Efavirenz for the Treatment of Creutzfeldt-Jakob Disease". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT07482085. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*